Research News

In a landmark study published recently in Chinese Neurosurgical Journal, Chinese researchers have identified the protein FAM111B as a crucial molecular accelerator in glioma, the most common and deadly form of primary brain cancer in adults.

Researchers at the University of Texas at Arlington (UTA) have identified a novel molecular mechanism by which chronic inflammation impairs cholesterol metabolism, potentially paving the way for new therapeutic strategies targeting inflammatory diseases and cardiovascular disorders.

Biological therapies have significantly improved the quality of life for many individuals suffering from severe asthma. However, new research from Karolinska Institutet in Sweden reveals that some inflammatory immune cells may persist in the bloodstream even after treatment, raising questions about the long-term effectiveness of these drugs.

A recent study by researchers at the Technical University of Munich (TUM) has uncovered a molecular mechanism that may explain how inflammation leads to neurodegeneration in patients with multiple sclerosis

A pioneering gene therapy engineered by researchers at the University of California San Diego (UCSD) School of Medicine demonstrates remarkable promise in halting, and potentially reversing, cognitive decline in preclinical Alzheimer’s models.

Eli Lilly and Company announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes

The study, published online in The Journal of Nutrition, found that consumption of 1-2 cups of caffeinated coffee per day was linked to a lower risk of death from all causes and death from cardiovascular disease.

Orion’s collaboration partner Bayer announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor , plus androgen deprivation therapy for marketing authorisation in the European Union for the treatment of patients with metastatic hormone-sensitive prostate cancer

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare autoimmune disease of the peripheral nervous system. This treatment modifies endogenous immune cells such that they can specifically target and eliminate B lymphocytes, which are here the origin of autoimmunity.